Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | DHODH | Q02127 | 5/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4863252 | 0.92 | ALDH1A1 (0.58) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL4003611 | 0.89 | ALDH1A1 (0.74) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL4009579 | 0.89 | ALDH1A1 (0.74) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL4010530 | 0.89 | ALDH1A1 (0.74) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL12828513 | 0.89 | ALDH1A1 (0.74) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL22756633 | 0.87 | ALDH1A1 (0.72) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL5199258 | 0.86 | ALDH1A1 (0.67) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL14335367 | 0.86 | ALDH1A1 (0.80) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL2406505 | 0.86 | ALDH1A1 (0.76) | ALDH1A1TSHRDHODHL3MBTL1HPGD | |
| SCHEMBL10806154 | 0.86 | ALDH1A1 (0.71) | ALDH1A1TSHRDHODHL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 245/4885TSHR 3836/4885DHODH 289/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 281/4885TSHR 3785/4885DHODH 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.